Skip to main content
. 2019 Jun 19;24(12):1514–1525. doi: 10.1634/theoncologist.2019-0019

Figure 4.

image

Progression‐free survival landmark analysis for patients experiencing palbociclib dose reduction versus no dose reduction. Landmark set at (A) 3 months, (B) 6 months, and (C) 9 months. Patients with a progression‐free survival time ≤ landmarks were excluded from the corresponding analysis.